Distinction between grade II ependymomas and anaplastic ependymomas based on histopathological examination solely is problematic and, therefore, the management of intracranial ependymomas remains controversial. The aim of this study was to conduct a systematic review (SR) and meta-analysis (MA) of data published on immunohistochemical prognostic markers (IPM) in intracranial ependymomas (IE), and to establish an evidence-based perspective on their clinical value. Following the extensive search based on a strictly defined group of key words, 30 studies reporting results on IPM in IE were identified. Due to a pronounced inter-study heterogeneity, only 14 publications fulfilled the criteria for inclusion into SR. From the total of 67 immunohistochemical markers, 18 were found to correlate with prognosis. However, owing to inadequate data publishing, MA could be performed only with data on proliferation marker MIB-1 (Ki-67) from 5 publications, including 337 patients: The pooled hazard ratio for overall survival was 3.16 (95% confidence interval = 1.96-5.09; p < 0.001) implicating that patients suffering from tumors with higher immunohistochemical expression of MIB-1 had a significantly worse outcome. Marked inter-study heterogeneity and incomplete data publishing in primary studies significantly limited extent of the SR, and the possibility of performing MA. Although the prognostic impact of MIB-1 immunoexpression in IE could be confirmed, there remains lack of further reliable IPM that could be used in routine diagnosis. We encourage to search for new, useful markers, as well as to standardize lab-techniques and data interpretation algorithms across laboratories in order to increase data compatibility.

2nd Medical School and University Hospital Motol Department of Pathology and Molecular Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Int J Cancer. 2001 May 20;95(3):144-51 PubMed

Pediatr Neurosurg. 1996;24(3):119-25 PubMed

Am J Surg Pathol. 2004 Jul;28(7):914-20 PubMed

Am J Clin Pathol. 2005 Oct;124(4):543-9 PubMed

J Neurosurg. 1998 Apr;88(4):695-703 PubMed

Neoplasma. 2004;51(3):214-22 PubMed

Neuropathology. 2006 Oct;26(5):422-8 PubMed

J Neurooncol. 1998 Oct;40(1):51-7 PubMed

Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(1):25-34 PubMed

J Neurooncol. 2002 Jan;56(1):21-8 PubMed

Clin Cancer Res. 2002 Oct;8(10):3054-64 PubMed

Stat Med. 1998 Dec 30;17(24):2815-34 PubMed

Am J Clin Pathol. 2003 Nov;120(5):699-705 PubMed

Br J Cancer. 2003 Apr 22;88(8):1191-8 PubMed

J Neurosurg. 1996 Oct;85(4):618-24 PubMed

Control Clin Trials. 1986 Sep;7(3):177-88 PubMed

Cancer. 1988 Jun 15;61(12):2433-8 PubMed

J Neurooncol. 2002 May;58(1):13-9 PubMed

Cancer. 2006 Jan 15;106(2):388-95 PubMed

J Neurosurg. 2000 Oct;93(4):605-13 PubMed

Childs Nerv Syst. 1992 Aug;8(5):273-8 PubMed

Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 PubMed

J Neurooncol. 1996 Feb;27(2):101-9 PubMed

Surg Neurol. 1988 Apr;29(4):271-81 PubMed

J Neurooncol. 2001 Aug;54(1):77-85 PubMed

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):4-12 PubMed

Acta Neuropathol. 2001 Sep;102(3):271-7 PubMed

Breast Cancer Res Treat. 1998;52(1-3):289-303 PubMed

Acta Neuropathol. 1993;85(5):495-502 PubMed

Neurosurg Rev. 1993;16(2):145-50 PubMed

J Neurooncol. 2002 Jul;58(3):255-70 PubMed

Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 PubMed

BMJ. 2001 Mar 3;322(7285):530 PubMed

J Neurooncol. 1999;45(3):219-27 PubMed

Acta Neuropathol. 1991;82(3):208-16 PubMed

Am J Clin Pathol. 1998 Nov;110(5):629-34 PubMed

Mod Pathol. 2003 Oct;16(10):980-91 PubMed

J Clin Oncol. 2006 Apr 1;24(10):1522-8 PubMed

Ann Diagn Pathol. 1999 Feb;3(1):11-8 PubMed

Neuropathol Appl Neurobiol. 1998 Dec;24(6):434-40 PubMed

Acta Neuropathol. 2005 Jan;109(1):69-92 PubMed

Acta Neuropathol. 2005 Feb;109(2):211-6 PubMed

Cancer. 2005 Jun 15;103(12):2598-605 PubMed